Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Treeline sees path to public markets via reverse merger
The deal is expected to close in the second half of this year and should leave Treeline with $900 million in cash, enough to last into 2029.
Darren Incorvaia
Jun 8, 2026 10:37am
J&J makes $1B bet on emerging DAC space by netting Firefly Bio
Jun 8, 2026 10:05am
Incyte inks $2B deal to add Star biz to late-phase constellation
Jun 8, 2026 9:07am
GSK pledges £44M to UK biotech to explore fibrosis regression
Jun 8, 2026 8:50am
Roche bets $700M upfront on Nurix’s late-phase BTK degrader
Jun 8, 2026 4:41am
Alnylam pays Inceptive $30M to transform siRNA design
Jun 4, 2026 4:13am
